Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia

Atherosclerosis

Volumn 188, Issue 1, 2006, Pages 203-212

  Tremblay, André J ^a   Lamarche, Benoît ^a,b   Ruel, Isabelle L ^a,b   Hogue, Jean Charles ^a   Deshaies, Yves ^c   Gagné, Claude ^a   Couture, Patrick ^a  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

Apolipoprotein B and A l kinetics; Dysbetalipoproteinemia; Familial hypercholesterolemia; Fenofibrate; Stable isotope

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; FENOFIBRATE; INTERMEDIATE DENSITY LIPOPROTEIN; LEUCINE; LOW DENSITY LIPOPROTEIN; STABLE ISOTOPE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CATABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; FAMILIAL HYPERCHOLESTEROLEMIA; HETEROZYGOSITY; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; IN VIVO STUDY; KINETICS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; MALE; PRIORITY JOURNAL;

ADULT; ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN B-100; APOLIPOPROTEIN B-48; APOLIPOPROTEINS; FENOFIBRATE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; HYPERLIPOPROTEINEMIA TYPE III; HYPOLIPIDEMIC AGENTS; KINETICS; MALE; PROCETOFEN; TRIGLYCERIDES;

EID: 33746503254     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.10.037     Document Type: Article

References (59)

1. Brewer H.J., Zech L., Gregg R., Schwartz D., and Schaefer E. NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann Intern Med 98 (1983) 623-640
2. Havel R.J. Familial dysbetalipoproteinemia. New aspects of pathogenesis and diagnosis. Med Clin North Am 66 (1982) 441-454
3. Mahley R.W., Huang Y., and Rall Jr. S.C. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 40 (1999) 1933-1949
4. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240 (1988) 622-630
5. Zannis V.I., Breslow J.L., Utermann G., et al. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res 23 (1982) 911-914
6. Mahley R.W., and Ji Z.S. Remnant lipoprotein metabolism. Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 40 (1999) 1-16
7. Davignon J., Gregg R.E., and Sing C.F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8 (1988) 1-21
8. Morganroth J., Levy R.l., and Fredrickson D.S. The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann Intern Med 82 (1975) 158-174
9. Goldstein J.L., Hobbs H.H., and Brown M.S. Familial hypercholesterolemia. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The metabolic basis of inherited diseases (1995), McGraw-Hill Publishing Co, New York 1981-2030
10. Moorjani S., Roy M., Gagné C., et al. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis 9 (1989) 211-216
11. Couture P., Vohl M.C., Gagne C., et al. Identification of three mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. Hum Mutat Suppl. 1 (1998) S226-S231
12. Sakuma N., Iwata S., Ikeuchi R., et al. Coexisting type III hyperlipoproteinemia and familial hypercholesterolemia: a case report. Metabolism 44 (1995) 460-465
13. Carmena R., Roy M., Roederer G., Minnich A., and Davignon J. Coexisting dysbetalipoproteinemia and familial hypercholesterolemia. Clinical and laboratory observations. Atherosclerosis 148 (2000) 113-124
14. Hobbs H.H., Brown M.S., and Goldstein J.L. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1 (1992) 445-466
15. Harris J., and Benedict F. A biometric study of basal metabolism in man (1919), Carnegie Institution, Washington, DC
16. Moorjani S., Dupont A., Labrie F., et al. Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism 36 (1987) 244-250
17. Havel R.J., Eder H., and Bragdon J. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34 (1955) 1345-1353
18. Albers J.J., Warnick G.R., Wiebe D., et al. Multi-laboratory comparison of three heparin-Mn2+ precipitation procedures for estimating cholesterol in high-density lipoprotein. Clin Chem 24 (1978) 853-856
19. Ruel I.L., Couture P., Cohn J.S., et al. Evidence that hepatic lipase deficiency in humans is not associated with proatherogenic changes in HDL composition and metabolism. J Lipid Res 45 (2004) 1528-1537
20. Hogue J.C., Lamarche B., Gaudet D., et al. Relationship between cholesteryl ester transfer protein and LDL heterogeneity in familial hypercholesterolemia. J Lipid Res 45 (2004) 1077-1083
21. Kotite L., Bergeron N., and Havel R.J. Quantification of apolipoproteins B-100, B-48, and E in human triglyceride-rich lipoproteins. J Lipid Res 36 (1995) 890-900
22. Zilversmit D.B., and Shea T.M. Quantitation of apoB-48 and apoB-100 by gel scanning or radio-iodination. J Lipid Res 30 (1989) 1639-1646
23. Batal R., Tremblay M., Krimbou L., et al. Familial HDL deficiency characterized by hypercatabolism of mature apoA-l but not proapoA-l. Arterioscler Thromb Vase Biol 18 (1998) 655-664
24. Welty F.K., Lichtenstein A.H., Barrett P.H., Dolnikowski G.G., and Schaefer E.J. Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes. Arterioscler Thromb Vase Biol 19 (1999) 2966-2974
25. Cobelli C., Toffolo G., Bier D.M., and Nosadini R. Models to interpret kinetic data in stable isotope tracer studies. Am J Physiol 253 (1987) E551-E564
26. Tremblay A.J., Lamarche B., Ruel I., et al. Lack of evidence for reduced plasma apo B48 catabolism in patients with heterozygous familial hypercholesterolemia carrying the same null LDL receptor gene mutation. Atherosclerosis 172 (2004) 367-373
27. Maugeais C., Ouguerram K., Krempf M., et al. A minimal model using stable isotopes to study the metabolism of apolipoprotein B-containing lipoproteins in humans. Diabetes Metab 22 (1996) 57-63
28. Winkler K., Schafer J.R., Klima B., et al. Lifibrol enhances the low density lipoprotein apolipoprotein B-100 turnover in patients with hypercholesterolemia and mixed hyperlipidemia. Atherosclerosis 144 (1999) 167-175
29. Tremblay A.J., Lamarche B., Ruel I.L., et al. Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation. J Lipid Res 45 (2004) 866-872
30. Parhofer K.G., Hugh P., Barrett R., Bier D.M., and Schonfeld G. Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes. J Lipid Res 32 (1991) 1311-1323
31. Aguilar-Salinas C.A., Barrett P.H., Parhofer K.G., et al. Apoprotein B-100 production is decreased in subjects heterozygous for truncations of apoprotein B. Arterioscler Thromb Vase Biol 15 (1995) 71-80
32. Cohn J., Wagner D., Cohn S., Millar J., and Schaefer E. Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-l production in human subjects using deuterated leucine. Effect of fasting and feeding. J Clin Invest 85 (1990) 804-811
33. Hixson J.E., and Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31 (1990) 545-548
34. Utermann G., Hees M., and Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature 269 (1977) 604-607
35. Goldstein J.L., Hobbs H.H., and Brown M.S. Familial hypercholesterolemia. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The metabolic basis of inherited diseases (2000), McGraw-Hill Publishing Co, New York 2863-2913
36. Huang Y., Liu X.Q., Rail Jr. S.C., and Mahley R.W. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins. J Biol Chem 273 (1998) 17483-17490
37. Weisgraber K.H. Apolipoprotein E: structure-function relationships. Adv Protein Chem 45 (1994) 249-302
38. Weisgraber K.H., Innerarity T.L., and Mahley R.W. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 257 (1982) 2518-2521
39. Chung B.H., and Segrest J.P. Resistance of a very low density lipoprotein subpopulation from familial dysbetalipoproteinemia to in vitro lipolytic conversion to the low density lipoprotein density fraction. J Lipid Res 24 (1983) 1148-1159
40. Ehnholm C., Mahley R.W., Chappell D.A., et al. Role of apolipoprotein E in the lipolytic conversion of beta-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia. Proc Natl Acad Sci USA 81 (1984) 5566-5570
41. Haffner S.M., Kushwaha R.S., and Hazzard W.R. Metabolism of chylomicrons in subjects with dysbetalipoproteinaemia (type III hyperlipoproteinaemia). Eur J Clin Invest 19 (1989) 486-490
42. Redgrave T.G., Watts G.F., Martins I.J., et al. Chylomicron remnant metabolism in familial dyslipidemias studied with a remnant-like emulsion breath test. J Lipid Res 42 (2001) 710-715
43. Stalenhoef A.F., Malloy M.J., Kane J.P., and Havel R.J. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia. J Clin Invest 78 (1986) 722-728
44. Turner P.R., Cortese C., Wootton R., et al. Plasma apolipoprotein B metabolism in familial type III dysbetalipoproteinaemia. Eur J Clin Invest 15 (1985) 100-112
45. Woollett L.A., Osono Y., Herz J., and Dietschy J.M. Apolipoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse. Proc Natl Acad Sci USA 92 (1995) 12500-12504
46. Guerin M., Dolphin P.J., and Chapman M.J. Preferential cholesteryl ester accepters among the LDL subspecies of subjects with familial hypercholesterolemia. Arterioscler Thromb 14 (1994) 679-685
47. Guerin M., Dolphin P.J., Talussot C., et al. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vase Biol 15 (1995) 1359-1368
48. Inazu A., Koizumi J., Mabuchi H., Kajinami K., and Takeda R. Enhanced cholesteryl ester transfer protein activities and abnormalities of high density lipoproteins in familial hypercholesterolemia. Horm Metab Res 24 (1992) 284-288
49. Tall A.R. Plasma cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies. J Intern Med 237 (1995) 5-12
50. Beisiegel U. New aspects on the role of plasma lipases in lipoprotein catabolism and atherosclerosis. Atherosclerosis 124 (1996) 1-8
51. Olivecrona G., and Olivecrona T. Triglyceride lipases and atherosclerosis. Curr Opin Lipidol 6 (1995) 291-305
52. Lamarche B., Uffelman K.D., Carpentier A., et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-l in healthy men. J Clin Invest 103 (1999) 1191-1199
53. Horowitz B.S., Goldberg I.J., Merab J., et al. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-l in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 91 (1993) 1743-1752
54. Lussier-Cacan S., Bard J.M., Boulet L., et al. Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III. Atherosclerosis 78 (1989) 167-182
55. Zhao S.P., Smelt A.H., Leuven J.A., et al. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil. Am J Med 96 (1994) 49-56
56. Staels B., Dallongeville J., Auwerx J., et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
57. Caslake M.J., Packard C.J., Gaw A., et al. Fenofibrate LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 13 (1993) 702-711
58. Vu-Dac N., Chopin-Delannoy S., Gervois P., et al. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-l expression by fibrates. J Biol Chem 273 (1998) 25713-25720
59. Chinetti G., Lestavel S., Bocher V., et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7 (2001) 53-58